A recent study suggests that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Research printed in a major health publication shows that while overweight individuals frequently drop about a fifth of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing these treatments need to be cognizant of the risk of rapid rebound weight gain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery implies a return to original weight within about 18 months.
Comparing Treatments
The study, which reviewed dozens of studies involving thousands of patients, compared the outcomes of these new drugs with older methods.
The team point out that people who shed pounds through lifestyle changes alone generally have a more gradual weight regain—approximately 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Nutrition scientists believe the mode of action of the jabs is key to understanding the amplified weight return.
The injections copy a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of GLP-1 levels far above than normal might result in the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement leads to appetite is unsuppressed, making excessive eating far more likely."
A Lifelong Disease?
Health authorities recommend the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Professionals contend that, considering the significant potential of weight regain, the treatment should be considered long-term.
This perspective is echoed by drug manufacturers, who note that the findings "underscore the chronic character of obesity," akin to managing diseases like hypertension.
User Accounts
Users who have come off the jabs explain a intense resurgence of hunger.
"It felt as if a trigger that goes on and I was suddenly starving," said a patient.
This challenge is exacerbated if patients have not adopted lasting lifestyle or habit changes during therapy.
Growing Interest
Survey data suggest that a significant number of people in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is greater among women than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, clinicians stress that while the jabs are powerful tools for shedding pounds, they are not a permanent fix and lasting health benefits relies on ongoing behavioural support.
